Bluejay Therapeutics expands management team and hired

Bluejay Therapeutics expands management team and hired

SAN MATEO, Calif., Sept. 21, 2023 (World NEWSWIRE) — Bluejay Therapeutics, Inc. a non-public clinical phase biopharmaceutical firm concentrated on viral and liver disorders, currently declared the appointment of Christopher Holterhoff as Senior Vice President, Head of Company Enhancement. Mr. Holterhoff will direct Bluejay’s business enterprise and corporate enhancement purpose and will play a considerable position in Bluejay’s corporate method and strategic setting up functions. He will be a member of Bluejay’s Executive staff, reporting to Keting Chu, Founder and CEO of Bluejay Therapeutics.

“I am delighted to welcome Chris to the senior management staff at Bluejay”, stated Mrs. Chu. “Chris has an exceptional observe record in business enterprise & company growth with each general public and personal biotech and pharma providers. His business improvement encounter, as nicely as his strategic aptitude will engage in a vital part as we execute on our vision of developing a foremost biotechnology company centered on healing treatment options for severe viral and liver diseases.”

“Bluejay is really very well-positioned with a pipeline of initial-in-class or most effective-in-class remedy alternatives addressing serious and remarkably commonplace viral and liver health conditions in which there exists substantial unmet health care want. I am thrilled to be a part of the group at these kinds of a pivotal time in its improvement, and I look forward to operating with Bluejay’s outstanding staff and leveraging my practical experience in company advancement to progress the company’s promising pipeline toward acceptance for clients who are in dire need of new procedure options.”

Mr. Holterhoff has approximately two decades of numerous encounter encompassing business enterprise & company progress, corporate finance & tactic, and funds marketplaces.

Before signing up for Bluejay, he served as VP, Enterprise & Corporate enhancement at LEXEO Therapeutics, where he led all company development, strategic transactions and played

Read More

Harpoon Therapeutics appoints Haibo Wang as SVP of business development

Harpoon Therapeutics appoints Haibo Wang as SVP of business development

Harpoon Therapeutics introduced Haibo Wang as its SVP of small business development this 7 days.

Wang, who joins Harpoon from Hummingbird Bioscience, has a qualifications of 15 a long time in biopharma business enterprise enhancement and finance, as properly as mergers and acquisitions.

At Hummingbird, Wang was VP of organization advancement. Prior to that, he served as director of organization progress at Amgen and served facilitate the company’s acquisitions of Teneobio and Five Key Therapeutics. Wang also aided strike scientific collaborations for Amgen’s most cancers pipeline, such as 1 with biotech BeiGene.

Wang’s occupation also features time used as a mergers and acquisitions marketing consultant at Deloitte.

“We are pleased to welcome Haibo as senior vice president of enterprise growth at Harpoon,” Julie Eastland, president and CEO of Harpoon Therapeutics, reported in a assertion. “Haibo’s extensive experience and strategic acumen will play a pivotal job in driving our business enterprise progress and forging impactful partnerships.”

Harpoon, which focuses on immunotherapies for most cancers, is now building T mobile engagers that trigger a patient’s T cells to target specified antigen-expressing cells, using its platform, Tri-precise T cell Activating Construct (TriTAC).

In March 2022, the pharma made the decision to discontinue its after-primary applicant for prostate most cancers and invest in other therapies. 

Its pipeline at the moment consists of 3 immunotherapies presently in Stage 1 trials – HPN328 (DLL3) for compact cell lung cancer, HPN217 (BCMA) for multiple myeloma, and HPN536 for ovarian cancer and other stable tumors. Harpoon is also executing preclinical work on 4 other therapies, together with a person in gastrointestinal cancers.

In April, Harpoon presented preclinical benefits on equally HPN217 and HPN328, saying the latter had “potential for long-phrase anti-tumor immunity and sturdy responses in individuals.”

“With our Stage 1 trial ongoing and further more reports

Read More